PriceTargets.com logo

Sigilon Therapeutics - SGTX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $49.50
  • Forecasted Upside: 120.29%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$22.47 As of 08/11/2023 09:00 PM ET
▼ -0.59 (-2.56%)
Get New Sigilon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGTX

Analyst Price Target is $49.50
▲ +120.29% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Sigilon Therapeutics in the last 3 months. The average price target is $49.50, with a high forecast of $78.00 and a low forecast of $21.00. The average price target represents a 120.29% upside from the last price of $22.47.

This chart shows the closing price for SGTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Sigilon Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/30/2023Morgan StanleyBoost TargetEqual Weight$7.00 ➝ $21.00Low
6/29/2023BTIG ResearchDowngradeBuy ➝ NeutralLow
1/18/2023Canaccord Genuity GroupInitiated CoverageBuy$78.00Low
11/30/2021Morgan StanleyLower TargetEqual Weight$117.00 ➝ $58.50High
11/30/2021BTIG ResearchReiterated RatingBuy$182.00High
11/30/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$195.00 ➝ $52.00High
10/29/2021BTIG ResearchInitiated CoverageBuy$182.00High
7/16/2021Morgan StanleyLower TargetEqual Weight$585.00 ➝ $117.00Low
12/29/2020BarclaysInitiated CoverageOverweight$624.00N/A
12/29/2020Morgan StanleyInitiated CoverageEqual Weight$585.00N/A
12/29/2020Jefferies Financial GroupInitiated CoverageBuy$780.00N/A
(Data available from 10/3/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2023
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/4/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sigilon Therapeutics logo
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $22.47
Low: $22.09
High: $23.10

50 Day Range

MA: $22.02
Low: $20.92
High: $23.06

52 Week Range

Now: $22.47
Low: $3.77
High: $28.00

Volume

83,600 shs

Average Volume

62,902 shs

Market Capitalization

$56.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Sigilon Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Sigilon Therapeutics in the last year: BTIG Research, Canaccord Genuity Group Inc., and Morgan Stanley.
View the latest analyst ratings for SGTX.

What is the current price target for Sigilon Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Sigilon Therapeutics in the last year. Their average twelve-month price target is $49.50, suggesting a possible upside of 120.3%. Canaccord Genuity Group Inc. has the highest price target set, predicting SGTX will reach $78.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $21.00 for Sigilon Therapeutics in the next year.
View the latest price targets for SGTX.

What is the current consensus analyst rating for Sigilon Therapeutics?

Sigilon Therapeutics currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SGTX, but not buy more shares or sell existing shares.
View the latest ratings for SGTX.

What other companies compete with Sigilon Therapeutics?

Other companies that are similar to Sigilon Therapeutics include AEON Biopharma, Clearside Biomedical, Immunic, Adagene and Rockwell Medical. Learn More about companies similar to Sigilon Therapeutics.

How do I contact Sigilon Therapeutics' investor relations team?

The company's listed phone number is 617-336-7540 and its investor relations email address is robert.windso[email protected]. The official website for Sigilon Therapeutics is sigilon.com. Learn More about contacing Sigilon Therapeutics investor relations.